

ABSTRACT OF THE DISCLOSURE

Neoplasia is treated by administering to a mammalian host a composition comprising
5 ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the
neoplastic cells and cytokines may be included to enhance the immune response. The
composition may be cells comprising expression constructs for the ligands, liposomes or
combinations of protein molecules.